Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Update

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 31,421 shares, a decrease of 38.5% from the April 15th total of 51,122 shares. Based on an average daily trading volume, of 23,330 shares, the short-interest ratio is presently 1.3 days. Approximately 0.1% of the company’s stock are short sold.

Zhengye Biotechnology Stock Up 0.3%

Zhengye Biotechnology stock traded up $0.00 during mid-day trading on Friday, hitting $0.95. The company had a trading volume of 4,401 shares, compared to its average volume of 70,488. Zhengye Biotechnology has a 1 year low of $0.68 and a 1 year high of $13.08. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 1.14. The business has a fifty day moving average of $0.92 and a 200 day moving average of $1.31.

Zhengye Biotechnology (NASDAQ:ZYBT) last announced its quarterly earnings results on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The business had revenue of $3.97 million for the quarter.

Hedge Funds Weigh In On Zhengye Biotechnology

A number of hedge funds have recently modified their holdings of ZYBT. Jane Street Group LLC purchased a new position in shares of Zhengye Biotechnology during the second quarter worth approximately $1,158,000. WINTON GROUP Ltd grew its position in shares of Zhengye Biotechnology by 193.8% during the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock worth $73,000 after acquiring an additional 41,750 shares during the last quarter. Invesco Ltd. purchased a new position in shares of Zhengye Biotechnology during the second quarter worth approximately $220,000. Geode Capital Management LLC purchased a new position in shares of Zhengye Biotechnology during the second quarter worth approximately $174,000. Finally, XTX Topco Ltd grew its position in shares of Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after acquiring an additional 24,697 shares during the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.